Capricor Therapeutics Inc. (NASDAQ:CAPR) is a biotechnology company focused on developing cell therapies for rare diseases. The company has recently gained attention due to its investigational treatment, Deramiocel, aimed at Duchenne muscular dystrophy (DMD), a severe genetic disorder. Capricor's competitors include other biotech firms working on similar therapies for rare diseases.
On December 3, 2025, Alliance Global Partners upgraded Capricor's stock to a "Buy" rating, with a price target increase from $16 to $48. At the time, the stock was priced at $29.19. This upgrade follows a significant surge in CAPR's stock price, which climbed 263% to $23.09 after achieving the main goal in a late-stage study for its cell therapy targeting a heart condition associated with DMD.
The stock's recent performance marks its highest levels since 2017, reaching an intraday high of $40.37. This upward movement breaks a previous trend of lower lows since a high of $20.04 on December 3. Year-to-date, CAPR has gained 87.6%, driven by a short squeeze with short interest increasing by 15%.
Capricor's recent success comes after a setback earlier this year when the FDA denied approval for Deramiocel, causing a 33% drop in the stock's value. However, the company plans to resubmit the treatment for approval, bolstered by promising results from its Phase 3 HOPE-3 trial. This trial involved 106 participants and demonstrated positive outcomes, boosting investor confidence.
Currently, CAPR is priced at $29.19, reflecting a 359% increase with a change of $22.83. The stock has fluctuated between a low of $21.50 and a high of $40.37 today, marking its highest price over the past year. With a market capitalization of approximately $1.33 billion and a trading volume of 42.14 million shares, Capricor is making significant strides in the biotech industry.
